Global InformationGapmer information
Gapmers are short DNA antisense oligonucleotide structures with RNA-like segments on both sides of the sequence.[1] These linear pieces of genetic information are designed to hybridize to a target piece of RNA and silence the gene through the induction of RNase H cleavage. Binding of the gapmer to the target has a higher affinity due to the modified RNA flanking regions, as well as resistance to degradation by nucleases.[2][3] Gapmers are currently being developed as therapeutics for a variety of cancers, viruses, and other chronic genetic disorders.[4]
- ^ Crooke, Stanley T.; Baker, Brenda F.; Crooke, Rosanne M.; Liang, Xue-hai (2021-03-24). "Antisense technology: an overview and prospectus". Nature Reviews Drug Discovery. 20 (6): 427–453. doi:10.1038/s41573-021-00162-z. ISSN 1474-1784. PMID 33762737. S2CID 232354935. Archived from the original on 2021-11-15. Retrieved 2021-04-30.
- ^ Dhuri, Karishma; Bechtold, Clara; Quijano, Elias; Pham, Ha; Gupta, Anisha; Vikram, Ajit; Bahal, Raman (2020-06-26). "Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development". Journal of Clinical Medicine. 9 (6): 2004. doi:10.3390/jcm9062004. ISSN 2077-0383. PMC 7355792. PMID 32604776.
- ^ QIAGEN. (2017). Antisense LNA GapmeRs Handbook: LNA-optimized oligonucleotides for strand-specific knockdown of mRNA and IncRNA. Germantown, MD: Author
- ^ Roberts, Thomas C.; Langer, Robert; Wood, Matthew J. A. (October 2020). "Advances in oligonucleotide drug delivery". Nature Reviews Drug Discovery. 19 (10): 673–694. doi:10.1038/s41573-020-0075-7. ISSN 1474-1784. PMC 7419031. PMID 32782413. S2CID 221097649.